Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Assets Average (2018 - 2025)

Historic Assets Average for Sutro Biopharma (STRO) over the last 8 years, with Q3 2025 value amounting to $236.0 million.

  • Sutro Biopharma's Assets Average fell 4983.25% to $236.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $236.0 million, marking a year-over-year decrease of 4983.25%. This contributed to the annual value of $429.0 million for FY2024, which is 224.88% down from last year.
  • As of Q3 2025, Sutro Biopharma's Assets Average stood at $236.0 million, which was down 4983.25% from $291.9 million recorded in Q2 2025.
  • Sutro Biopharma's 5-year Assets Average high stood at $470.4 million for Q3 2024, and its period low was $236.0 million during Q3 2025.
  • In the last 5 years, Sutro Biopharma's Assets Average had a median value of $382.5 million in 2023 and averaged $382.7 million.
  • As far as peak fluctuations go, Sutro Biopharma's Assets Average soared by 14259.5% in 2021, and later crashed by 4983.25% in 2025.
  • Sutro Biopharma's Assets Average (Quarter) stood at $356.4 million in 2021, then rose by 13.29% to $403.8 million in 2022, then grew by 11.74% to $451.2 million in 2023, then dropped by 7.03% to $419.5 million in 2024, then plummeted by 43.74% to $236.0 million in 2025.
  • Its Assets Average stands at $236.0 million for Q3 2025, versus $291.9 million for Q2 2025 and $354.3 million for Q1 2025.